BR1100574A - Ligantes macrocìclicos e complexos - Google Patents

Ligantes macrocìclicos e complexos

Info

Publication number
BR1100574A
BR1100574A BR1100574-2A BR1100574A BR1100574A BR 1100574 A BR1100574 A BR 1100574A BR 1100574 A BR1100574 A BR 1100574A BR 1100574 A BR1100574 A BR 1100574A
Authority
BR
Brazil
Prior art keywords
macrocyclic
complex ligands
ligands
complex
Prior art date
Application number
BR1100574-2A
Other languages
English (en)
Inventor
Roberta C Cheng
William A Fordyce
William F Goeckeler
William J Kruper
Sharon Braughman
Joseph R Garlich
Garry E Kiefer
Kenneh Macmillan
Jaime Simon
David A Wilson
Richard Keith Frank
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR1100574A publication Critical patent/BR1100574A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR1100574-2A 1988-06-24 1997-05-13 Ligantes macrocìclicos e complexos BR1100574A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21149688A 1988-06-24 1988-06-24

Publications (1)

Publication Number Publication Date
BR1100574A true BR1100574A (pt) 2000-06-06

Family

ID=22787153

Family Applications (2)

Application Number Title Priority Date Filing Date
BR1100574-2A BR1100574A (pt) 1988-06-24 1997-05-13 Ligantes macrocìclicos e complexos
BR1100580-7A BR1100580A (pt) 1988-06-24 1997-05-13 Composto e complexo

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR1100580-7A BR1100580A (pt) 1988-06-24 1997-05-13 Composto e complexo

Country Status (6)

Country Link
US (1) US5652361A (pt)
CN (2) CN1033030C (pt)
AU (1) AU3705889A (pt)
BR (2) BR1100574A (pt)
PT (1) PT90959B (pt)
ZA (1) ZA894792B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU623901B2 (en) * 1988-01-26 1992-05-28 Nycomed As Paramagnetic compounds comprising chelating moiety, linker group macro molecule and paramagnetic metal
JP2831073B2 (ja) * 1988-06-24 1998-12-02 ザ ダウ ケミカル カンパニー 大環状二官能キレート剤、その錯体及びそれらの抗体接合体
US6139603A (en) * 1989-02-22 2000-10-31 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Process for recovering oxygen
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
DE19652387A1 (de) * 1996-12-04 1998-06-10 Schering Ag Macrocyclische Metallkomplexcarbonsäuren, ihre Verwendung sowie Verfahren zu ihrer Herstellung
US6231832B1 (en) 1998-03-23 2001-05-15 Brookhaven Science Associates Radiopharmaceutical stannic Sn-117m chelate compositions and methods of use
EP1161451A4 (en) 1999-02-26 2006-05-17 Human Genome Sciences Inc HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP2431054A3 (en) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
KR101155294B1 (ko) 2000-06-16 2013-03-07 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
ATE451390T1 (de) 2000-08-18 2009-12-15 Dyax Corp Polypeptide zur bindung an das b-lymphozyten- stimulatorische protein (blys)
US6670456B2 (en) 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
EP2228389B1 (en) 2001-04-13 2015-07-08 Human Genome Sciences, Inc. Antibodies against vascular endothelial growth factor 2
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
AU2003209340A1 (en) * 2002-01-18 2003-09-02 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
CA2480052A1 (en) * 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
JP2005535572A (ja) 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
CA2488682C (en) * 2002-06-10 2014-04-01 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
NZ547591A (en) * 2003-12-04 2009-11-27 Vaccinex Inc Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
SI1729795T1 (sl) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albuminski fuzijski proteini
EP1768558A4 (en) 2004-06-09 2009-11-25 Kereos Inc LIPOPHILES DERIVATIVES OF CHELATE MONOAMIDES
EP1778699A4 (en) * 2004-08-10 2009-02-25 Dow Global Technologies Inc TARGETING OF CHELANTS AND CHELATES
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
EA015860B1 (ru) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
BRPI0709338A2 (pt) 2006-03-21 2011-07-12 Genentech Inc anticorpo, molécula de ácido nucleico isolada, célula, composições, método de detecção da proteìna alfa5beta1, uso de anticorpo, métodos de tratamento, kit, uso de uma composição, uso de uma antagonista de alfa5beta e uso de uma antagonista de vegf
US20090252675A1 (en) * 2006-03-29 2009-10-08 Frank R Keith Radionuclide Therapy for Urinary Bladder Cancer
JP2009544574A (ja) * 2006-06-22 2009-12-17 バクシネックス インコーポレーティッド 癌を処置するための抗ｃ３５抗体
EP2759549B1 (en) 2006-09-01 2015-08-19 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
GB0624587D0 (en) * 2006-12-08 2007-01-17 Univ Muenchen Tech Chelating agent
WO2008119036A2 (en) * 2007-03-27 2008-10-02 Radiomedix Inc. Compositions for targeted imaging and therapy
WO2009071696A2 (en) 2007-12-07 2009-06-11 Zymogenetics, Inc. Humanized antibody molecules specific for il-31
CN101932333A (zh) 2007-12-26 2010-12-29 瓦西尼斯公司 抗c35抗体联合疗法和方法
ES2712881T3 (es) * 2008-12-02 2019-05-16 Univ Melbourne Conjugados macrocíclicos que contienen nitrógeno como radiofármacos
EP2396035A4 (en) 2009-02-12 2012-09-12 Human Genome Sciences Inc USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
MX2011010012A (es) 2009-03-25 2011-12-06 Genentech Inc NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
WO2011141823A2 (en) 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
EP2721045B1 (en) 2011-06-20 2017-04-12 Radiomedix Inc. Compositions, methods of synthesis and use of carbohydrate targeted agents
JP6207504B2 (ja) 2011-07-07 2017-10-04 オーストラリアン ニュークリア サイエンス アンド テクノロジー オーガニゼーション クリプテート化合物
WO2013162748A1 (en) 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
WO2015184403A2 (en) 2014-05-30 2015-12-03 Henlius Biotech Co., Ltd. Anti-epidermal growth factor receptor (egfr) antibodies
CN114057857A (zh) 2014-06-20 2022-02-18 豪夫迈·罗氏有限公司 基于chagasin的支架组合物、方法和应用
EP3277314A4 (en) 2015-04-03 2018-08-29 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
KR102668727B1 (ko) 2015-04-24 2024-05-28 제넨테크, 인크. 다중특이적 항원-결합 단백질
RU2752832C2 (ru) 2016-09-16 2021-08-09 Шанхай Хенлиус Байотек, Инк. Анти-pd-1 антитела
WO2018132597A1 (en) 2017-01-12 2018-07-19 Eureka Therapeutics, Inc. Constructs targeting histone h3 peptide/mhc complexes and uses thereof
MY201065A (en) 2017-04-26 2024-02-01 Eureka Therapeutics Inc Constructs specifically recognizing glypican 3 and uses thereof
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
CN109384737A (zh) * 2017-08-04 2019-02-26 天津科伦药物研究有限公司 一种四氮杂环钇络合物及其制备方法和应用
CA3087423A1 (en) 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
SG11202012342WA (en) 2018-06-18 2021-01-28 Eureka Therapeutics Inc Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
PL4077288T3 (pl) * 2019-12-20 2024-04-08 Nuclear Research And Consultancy Group Rozdział chromatograficzny metali z użyciem chelatorów na bazie DOTA
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
EP4448578A1 (en) 2021-12-17 2024-10-23 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
AU2022411573A1 (en) 2021-12-17 2024-06-27 Shanghai Henlius Biologics Co., Ltd. Anti-ox40 antibodies and methods of use
WO2023179740A1 (en) 2022-03-25 2023-09-28 Shanghai Henlius Biotech , Inc. Anti-msln antibodies and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
SE8301395L (sv) * 1983-03-15 1984-09-16 Wallac Oy Kelatiserande foreningar med funktionella grupper vilka tillater kovalent koppling till bio-organiska molekyler
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
DE3772785D1 (de) * 1986-01-23 1991-10-17 Squibb & Sons Inc 1-substituiertes-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecan und analoga.
US4885363A (en) * 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound
DE3625417C2 (de) * 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
US5057302A (en) * 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
US4994560A (en) * 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
GB8719041D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds

Also Published As

Publication number Publication date
AU3705889A (en) 1990-01-04
PT90959B (pt) 1995-05-04
US5652361A (en) 1997-07-29
CN1050836C (zh) 2000-03-29
CN1109469A (zh) 1995-10-04
CN1044095A (zh) 1990-07-25
CN1033030C (zh) 1996-10-16
PT90959A (pt) 1989-12-29
ZA894792B (en) 1991-04-24
BR1100580A (pt) 2000-06-06

Similar Documents

Publication Publication Date Title
BR1100574A (pt) Ligantes macrocìclicos e complexos
DK60691D0 (da) Cyclodextrin-peptidkomplekser
TR23587A (tr) Gizli
TR23588A (tr) Gizli
MC2034A1 (fr) Preparations
DK348289A (da) Forbindelser
NO905485L (no) Benzazepin- og benzotiazepin-derivater.
KR900702583A (ko) 초전도성 복합체
DK245188D0 (da) Stoej- og vibrationsdaempende materialer
DE68908037D1 (de) Polyaetherimid-mischungen und formverfahren.
TR23848A (tr) Gizli
DK84489A (da) Praeparater
FI91488B (fi) Seula
KR890016710U (ko) 솔레노이드
KR900004691A (ko) 페닐피리딘 및 이의 제조방법
FI896020A0 (fi) Koordinatnaet foer en stereoskopisk maetanordning.
TR23466A (tr) Gizli
IT8812575A0 (it) Parallelografo e tecnigrafo
SE8902995D0 (sv) Trappa och trappsteg
MX15190A (es) Complejo de derivados de telurio y silenio.
DK182189D0 (da) Platinkomplekser
BR8803850A (pt) Domino trilatero
TR23589A (tr) Gizli
TR23465A (tr) Gizli
TR23461A (tr) Insektisid oezellikte suebstituee edilmis inolazoller

Legal Events

Date Code Title Description
AN Processing applications according to articles 230 and 231 of law 9279/96: notification of filing an application
HHFK Processing applications according to articles 230 and 231 of law 9.279/96: republication
MT Patent procedure suspended until requirement met - articles 230 and 231 of law 9279/96
MT Patent procedure suspended until requirement met - articles 230 and 231 of law 9279/96
FGAN Processing applications according to articles 230 and 231 of law 9.279/96: granting
NB Patent issued - articles 230 and 231 of law 9279/96